The collaboration between two companies may pave the way for the development of new therapy options for neuroendocrine tumors: Covidien LTd, a global provider of healthcare products and BioSynthema Inc., a company specialized in the discovery and development of molecular targeted biophamaceuticals recently signed an agreement that will gain BioSynthema access to specific Covidien proprietary…
Every developing tissue is supplied by blood vessels with oxygen and nutrients. Tumours grow far more quickly than normal tissues, so have a greater need of nutrients, which is why tumour cells begin to produce growth factors that stimulate the formation of blood vessels.
GS1 is the leading global standards organisation in the healthcare industry. In 56 countries worldwide, GS1 standards have been chosen to identify pharmaceutical products uniquely. Major regulatory bodies have endorsed them, including those in the US, Japan and the UK . It standards improve patient safety and reduce costs in the healthcare supply chain. Automatic product identification on all…
Carestream's molecular imaging group focuses on life sciences, developing high-performance digital imaging systems, imaging agents, film and accessories for the research and drug discovery/development markets.
Influenza infects around 20% of the US population and results in 200,000 hospitalisations annually. It kills about 36,000 citizens. In the USA, only 36% of all healthcare workers are immunised against influenza annually, and now the American College of Physicians (ACP)
The British Midlands' University of Nottingham discovered a possible vaccine for use in the treatment of Hepatits C. At the 161st. meeting of the Society for General Microbiology in Edinburgh, UK, a paper titled “Human Antibodies to Hepatits C Virus – Potential for Vaccine Design” was presented.
Researchers from the Robert Gordon University in Aberdeen, UK, presented a study at The British Pharmaceutical Conference, held from 10th to 12th September, 2007, at Manchester Central, showing that a chemical coating is able to encapsulate and protect insulin against enzymes that usually break down the hormone in the gastrointestinal tract.
UK & France - The Hypertension in the Very Elderly Trial (HYVET), the biggest global clinical trial to assess the benefits of lowering blood pressure in patients aged 80+, was halted in July, two years before its scheduled completion in 2009.
The Glide Solid Dose Injector (SDI), the needle-free drug delivery system that injects drugs in solid dosage form into the skin, has contributed to its manufacturer, Glide Pharma, winning the Best Business Award at the 2007 Medical Futures Innovation Awards.
The Swiss company Novartis recently received the FDA approval for the U.S. market for their new osteoporosis drug “Reclast”, a therapy that is only given once a year via a 15-minute infusion. The new treatment option is especially designed for women who suffer from post-menopausal osteoporosis.
Case 1 50-year-old male with a colorectal cancer. Greyscale imaging clearly shows the lesion, as an echogenic 3 cm mass (Fig.l a), which must be considered as suspicious for a metastasis from his colorectal cancer but benefit of the doubt must be given. Colour Doppler (Fig. 1b) is not helpful. At 33 seconds after SonoVue injection (early sinusoidal phase), Vascular Recognition Imaging (VRI)…
A study of european scientists reveals that misfolded amyloid beta proteins, generally regarded as the cause for Alzheimer's disease, could also cause glaucoma. The scientists tested several drugs and their effect on the progression of glaucoma - pharmaceuticals usually used to treat Alzheimer's disease had most effect.
Phosphagenics' TPM uses natural dermal transport mechanisms to deliver a dose of medication through the skin into the bloodstream. Now a Phase 1b transdermal insulin trial was completed successfully.
“Exelon Patch”, developed by Novartis is the first skin patch to treat patients with mild to moderate Alzheimer disease. The new therapy that has already been approved by the FDA, is said to be more compliant for it causes less incidents of nausea and vomiting.
Celebrating his 71st birthday this year, Czech chemist Professor Antonin Holy will also be able to celebrate the launch of clinical testing of a drug to treat non-Hodgkins Lymphoma (NHL) and chronic lymphatic leukaemia (CLL) - adding another to his 60+ registered patents.
Today little is known about the metabolism of the tuberculosis bacillus and, because of its slow growth, experiments for new drugs take a long time. Now a team of researchers form the University of Surrey built an in silico model of the agent that causes TB - a virtual TB bacillus - that promises to speed up the drug discovery process.
Congress President Professor Juergen Dunst MD praises major advances and multidisciplinary efforts, and outlines future hopes for breast cancer patients
The European Parliament voted for an EU Regulation on advanced therapies like gene therapy, cell therapy and tissue engineering. The decision, if adopted by the council, could open the door for innovative therapies which have a huge potential for curing diseases such as Parkionson´s, Alzheimer or cancer.
When the Siemens board of directors announced its decision for the new Siemens CEO on Sunday, the economic world was surprised: Not only that the name Peter Löscher was never mentioned in the previous discussions about a successor of Klaus Kleinfeld, but hardly anybody knew Loescher´s name in any enconomic context.
'Ultrasound-guided interventional pain therapy originates in ultrasound guided regional anaesthesia,' Dr Eichenberger explained.
Researchers have made a breakthrough by detecting the electrical equivalent of a living cell's last gasp. The work takes them a step closer to both seeing the 'heartbeat' of a living cell and a new way to test drugs.
The beautiful weather not only causes high spirit but also seasonal allergies. And as every year, over-the-counter allergy medications are booming, whereas most of the patients are extremely thoughtless concerning the use of antihistamines, not being aware of the side effects.
Due to a revised EU law, manufactures of medical devices are forced to label certain chemical ingredients in their products. This decision will enable hospitals to protect their patients against harm caused by toxic devices - if they are interested in. Because alternative products of course are connected with higher costs.
Many French pharmacists are falling on hard times after a year of falling revenues. Those most affected are in rural or semi-rural areas, where there is a growing shortage of doctors willing to set up practice or where resident GPs are leaving for the more populous towns.